ABBV-324
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 13, 2025
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
(clinicaltrials.gov)
- P1 | N=232 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting
Adverse events • Enrollment open • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma
March 05, 2025
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
(clinicaltrials.gov)
- P1 | N=232 | Not yet recruiting | Sponsor: AbbVie
Adverse events • New P1 trial • Hepatocellular Cancer • Hepatology • Liver Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma
1 to 2
Of
2
Go to page
1